Table 1. Baseline characteristics of the study participants.
n = 122 | |
---|---|
Gender (male/female) | 72/50 |
Age (years) | 61.0 ± 13.0 |
BMI (kg/m2) | 26.4 ± 5.1 |
Diabetes duration (years) | 10.7 ± 9.3 |
Hypertension, n (%) | 73 (60) |
Dislipidemia, n (%) | 89 (73) |
SBP (mmHg) | 131.7 ± 17.7 |
DBP (mmHg) | 75.1 ± 12.0 |
History of smoking (%) | 60 (49) |
Total cholesterol (mg/dL) | 187.4 ± 34.5 |
Triglyceride (mg/dL) | 138.3 ± 70.2 |
HDL cholesterol (mg/dL) | 52.2 ± 16.3 |
LDL cholesterol (mg/dL) | 110.0 ± 30.0 |
eGFR (ml/min per 1.73 m2) | 77.4 ± 23.6 |
Fasting blood glucose (mg/dL) | 153.6 ± 51.1 |
HbA1c (%) | 8.57 ± 2.33 |
Urinary 8-isoprostane (pg/mgCr) | 265.2 ± 264.2 |
Urinary 8-OHdG (ng/mgCr) | 11.4 ± 7.9 |
MDA-LDL (U/dl) | 133.0 ± 42.3 |
Nε-(carboxymethyl) lysine (µg/ml) | 3.49 ± 0.96 |
3-deoxyglucosone (ng/ml) | 24.37 ± 14.2 |
max IMT (mm) | 1.64 ± 0.70 |
mean baPWV (cm/s) | 1569.4 ± 311.4 |
mean ABI | 1.13 ± 0.96 |
Coronary artery calcification score, (AU) | 197.03 ± 412.78 |
Skin autofluorescence (AU) | 2.42 ± 0.417 |
Metformin, n (%) | 52 (43) |
DPP-4 inhibitors, n (%) | 53 (44) |
Statins, n (%) | 50 (41) |
RAS inhibitors, n (%) | 61 (50) |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobinA1c; OHdG, hydroxydeoxyguanosine; MDA-LDL, malondialdehyde modified low density lipoprotein; IMT, intima-media thickness; baPWV, brachial ankle pulse wave velocity; ABI, ankle brachial index; DPP, dipeptidyl peptidase; RAS, renin-angiotensin system